EU universities are miserably lax at reporting clinical trial results, analysis suggests
The value of publishing clinical trial data cannot be exaggerated — it is crucial to the pace and direction of scientific progress, and critical to the knowledge base employed by patients, doctors and policymakers to make decisions about the safety, benefits and adoption of treatment interventions. But not everybody is quite as concerned with the toll clinical trial transparency transgressions can take on patient health, public health policy and medical advancement — a new report suggests European Universities are extraordinarily guilty of these reporting violations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.